Figure 1
The proportion of ATT-treated patients in V5 and placebo arms who have benefited from the therapy according to the measured endpoints.
Figure 1 | Journal of Immune Based Therapies and Vaccines
The proportion of ATT-treated patients in V5 and placebo arms who have benefited from the therapy according to the measured endpoints.